Q-omics provides the consensus-scored ARGFXP1 profile across patient tissues and cancer cell-line models. ARGFXP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, ARGFXP1 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, ARGFXP1 RNA expression shows 6,567 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, BRCA, and STAD as cancer lineages where ARGFXP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARGFXP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARGFXP1 survival associations across molecular data types. ARGFXP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARGFXP1 RNA expression–survival associations across cancer types. High ARGFXP1 expression shows unfavorable associations in THYM, LIHC, KICH, THCA, LUSC and COAD. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for ARGFXP1 RNA expression.
This table summarizes ARGFXP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARGFXP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARGFXP1 shows lower tumor expression in LUAD and higher tumor expression in BRCA, THCA and KIRP. The BRCA box plot shows higher ARGFXP1 RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p < 0.001).
This table shows molecular features associated with ARGFXP1 in patient tissues and cancer cell lines. In patient samples, ARGFXP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
